ActoGeniX, a Dutch biopharmaceutical developer and spin-off from VIB and Ghent University, has secured a �3.1 million ($4.2 million) grant from the Flanders government. The money follows a Series A round where it raised �20 million from Biotech Flanders, GIMV, Life Sciences Partners, Aescap Venture, Baekeland Fonds and Ventech, reports vw. www.actogenix.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.